Dose Level 2-Baylor College of Medicine-leukemia-myelodysplastic syndrome

Dose Level 2-Baylor College of Medicine-leukemia-myelodysplastic syndrome refers to a specific dosage strength of an investigational autologous cell-based immunotherapy developed by the Baylor College of Medicine Center for Cell and Gene Therapy. This personalized treatment is designed for patients with high-risk acute leukemia or myelodysplastic syndrome (MDS). The therapy consists of a mixture of the patient's own leukemic blast cells and autologous skin fibroblasts that have been genetically modified using adenoviral vectors to express human CD40 ligand (CD40L) and interleukin-2 (IL-2). Dose Level 2 specifically contains 2 x 10^7 leukemic blasts, 2 x 10^7 IL-2-secreting fibroblasts, and 2 x 10^5 CD40L-expressing fibroblasts. Administered via subcutaneous injection, the treatment aims to overcome tumor-induced immune suppression by providing potent costimulatory signals through CD40 activation and promoting T-cell expansion via IL-2 signaling, thereby inducing a systemic anti-leukemic immune response.

Other names

CD40L and IL-2 gene-modified autologous fibroblasts and leukemic blastsCD-40L and IL-2 gene-modified autologous fibroblasts and leukemic blastsCD 40L and IL-2 gene-modified autologous fibroblasts and leukemic blastsTreatment of High Risk Acute Leukemia With CD40 Ligand and IL-2 Gene Modified Autologous Skin Fibroblasts and Tumor CellsAd-hCD40L/Ad-hIL-2 modified fibroblasts + leukemic blasts